Immunotherapy before surgery for pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs (durvalumab and oleclumab) given before surgery to people with pancreatic cancer that can be removed. The goal is to see if this treatment helps the immune system fight the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic ductal adenocarcinoma (PDAC) that can be surgically removed
- You are in good overall health (able to do daily activities without help or with light work)
- You weigh at least 35 kg (about 77 lbs)
- You have not had immunotherapy or certain other cancer treatments in the past
- You do not have an active autoimmune disease or serious heart problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
This trial tests a new approach that combines a special type of radiation therapy (called PRaG) with an immunotherapy drug to treat advanced pancreatic cancer that hasn't spread. The goal is to see if this combination can shrink or control the tumor and help you live longer.
This trial tests a combination of immunotherapy drugs (targeting CD40 and other immune cells) as a maintenance treatment for people with advanced pancreatic cancer that has not grown or has shrunk after initial chemotherapy. The goal is to see if this approach can keep the cancer from progressing longer.
This trial tests a procedure that uses sound waves to heat and destroy part of the tumor, combined with an immunotherapy drug called pembrolizumab (Keytruda) that helps your immune system fight the cancer. It is for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a combination of a chemotherapy drug (irinotecan liposome) plus an immunotherapy drug (addebelizumab) given before surgery to people with pancreatic cancer that can be fully removed. The goal is to see if this treatment reduces the chance of the cancer coming back and improves outcomes.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.